Take away the red and white blood cells from blood and you get plasma, a protein-rich fluid. CSL Behring is among the world's largest fully integrated plasma collection companies. Through subsidiary
, the firm collects plasma from dozens of facilities in the US and Germany. CSL Behring then develops plasma-based protein biotherapeutics to treat a range of health ailments, including bleeding disorders (such as hemophilia), immune system deficiencies (including von Willebrand disease), and respiratory disease (including emphysema). Biotherapeutics are also used in critical care settings for surgical and wound healing applications. CSL Behring is a subsidiary of Australia's
CSL Behring has biotherapeutic manufacturing operations in the US, Germany, and Switzerland, and it has satellite sales offices in another 20 countries worldwide. Plasma collection subsidiary CSL Plasma operates more than 120 plasma collection centers in the US and Europe. CSL Plasma is one of the world's largest plasma collection networks.
The company boasts a global presence through its more than two dozen regional sales offices. Outside the US, CSL Behring sells products in Argentina, Austria, Belgium/Luxemburg, Brazil, Canada, China, Denmark, France, Germany, Greece, Hong Kong, Italy, Japan, Mexico, the Netherlands, Sweden, Portugal, Spain, Switzerland, and the UK. The company maintains research and development facilities in Illinois and Pennsylvania, as well as overseas in Germany and Switzerland. Manufacturing takes place in Australia, Germany, Switzerland, and in the US in Illinois.
CSL Behring provides 93% of parent company CSL Limited's total revenues.
In 2014, CSL Behring's revenue grew 10% to $4.9 billion as demand increased across all geographic markets. Immunoglobins accounted for the largest amount of earnings and sales rose 12% that year; albumin rose 16% due to higher demand in China. Specialty product sales also rose, increasing 18% after its prothrombin complex concentrate Kcentra was approved for the US market.
To expand its product line to treat a wider variety of diseases, CSL Behring regularly conducts research and development activities both internally and through partnerships. The process is time-consuming and tedious. In 2015 it was given approval to bring Respreeza (a treatment for Alpha-1 antitrypsin deficiency, or AATD) to market in Europe. In late 2013, CSL Behring gained approval for prothrombin complex concentrate Kcentra in the US.
CSL Behring opened a new manufacturing facility in Australia in 2014. The biotechnology facility was designed to produce novel recombinant therapies for a range of serious and rare diseases.
The company is also working to expand its presence in emerging markets.
CSL Behring takes the second part of its name from Emil von Behring, a German doctor who worked to find treatments for infectious diseases. Formerly known as ZLB Behring, the company was formed in 2004 when parent CSL Limited acquired Aventis Behring and merged it with its ZLB Bioplasma unit.